Compare CarMax, Inc (KMX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Zoetis Inc — how do they compare? CarMax, Inc trades at $58.6 (market cap $8.26B), while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 3.8× CarMax, Inc's market cap, and Zoetis Inc pays a 2.81% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| KMX | ZTS | |
|---|---|---|
Market Cap | $8.26B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $62.17 | $156.76 |
52-Week Low | $30.88 | $71.91 |
Enterprise Value | $26.77B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $58.705, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q2 2025 but beating in Q3 2025 and Q1 2026, with net income of $500.56M in 2025. Recent news includes a Zacks Strong Buy rating and a partnership with Sierra to enhance customer service, though ongoing legal investigations pose a headwind.
The stock's outlook is cautiously optimistic, supported by improving cash flow trends and analyst buy ratings, but risks include high debt levels and margin pressures. With a consensus price target of $53.09 below the current price, near-term upside may be limited despite positive momentum indicators.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
